Royal Bank Of Canada reaffirmed their sector perform rating on shares of Integra LifeSciences (NASDAQ:IART) in a report released on Thursday, November 9th, MarketBeat Ratings reports. They currently have a $50.00 target price on the life sciences company’s stock, up from their previous target price of $48.00.
A number of other analysts have also recently commented on the stock. UBS reiterated a buy rating and issued a $57.00 target price on shares of Integra LifeSciences in a research note on Tuesday, October 31st. Wells Fargo & Company cut shares of Integra LifeSciences from an outperform rating to a market perform rating in a research report on Sunday, October 29th. Jefferies Group reaffirmed a buy rating and issued a $56.00 target price on shares of Integra LifeSciences in a research report on Sunday, October 29th. TheStreet cut shares of Integra LifeSciences from a b rating to a c+ rating in a research report on Thursday, October 26th. Finally, J P Morgan Chase & Co cut shares of Integra LifeSciences from an overweight rating to a neutral rating and set a $44.00 price target on the stock. in a research report on Friday, October 27th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $53.82.
Integra LifeSciences (IART) opened at $48.46 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. Integra LifeSciences has a 12-month low of $37.71 and a 12-month high of $56.42. The stock has a market cap of $3,800.00, a P/E ratio of 26.76, a PEG ratio of 2.12 and a beta of 0.64.
In related news, Director Barbara B. Hill purchased 10,768 shares of the company’s stock in a transaction on Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the purchase, the director now directly owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Richard D. Gorelick sold 1,500 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the completion of the transaction, the vice president now owns 21,665 shares in the company, valued at $1,022,371.35. The disclosure for this sale can be found here. 21.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in IART. Eagle Asset Management Inc. lifted its position in Integra LifeSciences by 39.0% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,647,018 shares of the life sciences company’s stock worth $89,778,000 after acquiring an additional 461,977 shares in the last quarter. Strs Ohio grew its stake in Integra LifeSciences by 60.4% during the 2nd quarter. Strs Ohio now owns 7,700 shares of the life sciences company’s stock worth $419,000 after buying an additional 2,900 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Integra LifeSciences by 116.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 244,982 shares of the life sciences company’s stock worth $10,322,000 after buying an additional 131,995 shares during the last quarter. Jennison Associates LLC grew its stake in Integra LifeSciences by 12.3% during the 2nd quarter. Jennison Associates LLC now owns 697,772 shares of the life sciences company’s stock worth $38,036,000 after buying an additional 76,548 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its stake in Integra LifeSciences by 80.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 11,939 shares of the life sciences company’s stock worth $650,000 after buying an additional 5,309 shares during the last quarter. Institutional investors own 87.59% of the company’s stock.
WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/integra-lifesciences-holdings-corporation-iart-earns-sector-perform-rating-from-royal-bank-of-canada/1772271.html.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with our FREE daily email newsletter.